IVERIC bio (ISEE) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares.
View ISEE analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12-month price objectives for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's stock price to reach $27.45 in the next twelve months. This suggests that the stock has a possible downside of 27.4%.
View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts.

IVERIC bio's stock was trading at $21.41 at the beginning of the year. Since then, ISEE stock has increased by 76.6% and is now trading at $37.80.
View the best growth stocks for 2023 here.

IVERIC bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 11,850,000 shares, an increase of 14.5% from the April 30th total of 10,350,000 shares. Based on an average trading volume of 3,750,000 shares, the short-interest ratio is currently 3.2 days.
View IVERIC bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our ISEE earnings forecast.

IVERIC bio, Inc. (NASDAQ:ISEE) posted its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS.

ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), American Century Mid Cap Growth Impact (MID), Harbor Health Care ETF (MEDI) and Principal Healthcare Innovators ETF (BTEC).

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.39%), Price T Rowe Associates Inc. MD (4.97%), State Street Corp (4.08%), American Century Companies Inc. (2.95%), Braidwell LP (2.71%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends.

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISEE stock can currently be purchased for approximately $37.80.

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.21 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.